

Letters to the Editor

Relief of SSRI-Induced Sexual Dysfunction With Mirtazapine Treatment

Sir: Sexual dysfunction is a known integral component of depressive illnesses, and most antidepressant drugs have been associated with sexual dysfunction, especially those agents with increased serotonergic activity.¹⁻⁴ In fact, the use of selective serotonin reuptake inhibitors (SSRIs) has been associated with significant ejaculatory dysfunction and orgasm-related difficulties.^{1,4-6} However, the incidence of sexual dysfunction varies with SSRIs. The package inserts report a range from 2% (fluoxetine) up to 20% (sertraline, paroxetine),^{5,7} and in the clinical setting, sexual dysfunction has been reported to occur in 7.8% to 75% of depressed patients.⁵⁻⁸ These differences in reported incidences may be due to a number of factors including duration of study, patients' inhibitions about reporting sexual dysfunction, lack of inquiry on the part of the clinician, or differences in the parameters used to elicit sexual function information (i.e., rating scales).^{1,4,5,7} In the study with the highest incidence of sexual dysfunction, patients were routinely questioned about their sexual function.⁸

Various strategies have been used to manage antidepressant-induced sexual dysfunction; these include drug holidays, lowering the dosage, switching agents, and adjunctive therapy.^{5-7,9} Spontaneous reductions in sexual side effects have been reported toward the end of a 6- to 8-week treatment period.^{1,2} However, in the clinical setting, patients may not wait for spontaneous reductions and often discontinue their antidepressant therapy. Agents such as cyproheptadine, yohimbine, and amantadine have been reported to be helpful as adjunctive therapy.¹⁰⁻¹² Other strategies include switching to an antidepressant that does not carry this risk: bupropion, nefazodone, or mirtazapine.^{1,5,13-15}

Mirtazapine, a potent 5-HT₂ and 5-HT₃ antagonist along with α_2 -antagonistic properties, has been reported to have little or no incidence of sexual dysfunction.^{3,16} Since sexual side effects related to SSRI treatment are believed to be mediated through 5-HT₂ stimulation, possible relief of symptoms may result from blocking these receptors with mirtazapine.^{16,17} Reports that mirtazapine reverses sexual side effects of ongoing SSRI therapy led to the following case reports.¹³⁻¹⁵

The following case series describes 4 patients who experienced sexual dysfunction while on SSRI therapy and consented to a trial of add-on, open-label mirtazapine therapy. Response to sexual functioning was either spontaneously reported (2 patients) or actively elicited (2 patients).

Case 1. A 47-year-old woman with a past medical history of alcohol dependence and premenstrual syndrome responded to paroxetine, 20 mg/day, for panic attacks and generalized anxiety, yet lack of libido was noted by 8 weeks of therapy. She had previously discontinued treatment with fluoxetine, 40 mg/day, for 1 year because of sexual dysfunction. She reported sexual intercourse at least 2 times per week (baseline libido) prior to SSRI therapy. Mirtazapine, 15 mg at bedtime, was added, and at her next medication check 6 weeks later, she reported restoration of

baseline sexual desire. Return of normal libido remains after 5 months of treatment with mirtazapine.

Case 2. A 30-year-old woman with a past medical history for chronic depression (> 3 years) had been treated with numerous antidepressants such as sertraline, venlafaxine, and bupropion with no response. However, this patient did respond to treatment with fluoxetine, 30 mg/day, but complained of loss of libido after 6 weeks of therapy. Mirtazapine, 15 mg at bedtime, was added, and libido returned to baseline within 2 months. This patient has sustained her normal libido for 3 months of mirtazapine treatment.

Case 3. A 36-year-old woman with a past medical history for posttraumatic stress disorder after a car accident responded well with paroxetine and zolpidem therapy. After 3 weeks of treatment with paroxetine, 30 mg/day, anorgasmia and decreased libido became prominent. Both of these symptoms improved within 1 week of initiating treatment with mirtazapine, 15 mg at bedtime. However, she discontinued this agent due to weight gain associated with increased appetite.

Case 4. A 49-year-old woman with depression reported "no sexual desire" after 2 months of paroxetine therapy. Her daily dose of paroxetine was 30 mg/day, and she was also taking clonazepam, 0.5 mg twice a day, for anxiety and insomnia. Mirtazapine, 15 mg/day, was added to her regimen at bedtime, and within a month she reported restoration of normal libido. Since then, her libido has been sustained for 2 months of mirtazapine treatment.

The cases reported herein demonstrate that mirtazapine may be beneficial in patients with SSRI-induced sexual dysfunction. These findings are consistent with the clinical pharmacology of mirtazapine, in that blockade of 5-HT₂ receptors may be related to lack of sexual side effects. All 4 patients reported resolution of their sexual side effects, which included anorgasmia and lack of libido, shortly after mirtazapine was added to their regimens. Criticisms of these cases may be that not all patients were questioned about sexual dysfunction and rating scales were not used to determine the level of sexual dysfunction at baseline, after initiation of SSRI therapy, and after initiation of mirtazapine therapy. However, once it was determined that the patients had sexual dysfunction, they were successfully treated with mirtazapine. Another concern could be that mirtazapine may have been added too early to the drug regimen. However, mirtazapine therapy was added after at least 6 to 8 weeks of SSRI therapy, which would have allowed for spontaneous reductions in sexual dysfunction. In most instances reported in the literature, the level of sexual dysfunction decreases by the end of the first 8 weeks of SSRI therapy.^{1,2} However, this was not the case with my patients because sexual function had not improved over the first 8 weeks of their SSRI therapy. One patient discontinued mirtazapine therapy because of weight gain.

SSRI therapy is known to carry the risk of sexual dysfunction,¹⁻⁴ and clinicians are often faced with the challenge of finding effective treatment strategies without compromising patient response to a particular agent. Controlled investigation is war-

ranted to fully determine the effect of mirtazapine on SSRI-induced sexual side effects.

REFERENCES

1. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. *J Clin Psychiatry* 1996;57(suppl 2):53-62
2. Harrison WM, Rabkin JG, Ehrhardt AA, et al. Effects of antidepressant medication on sexual function: a controlled study. *J Clin Psychopharmacol* 1986;6:144-149
3. Stahl SM. Basic psychopharmacology of antidepressants, pt 1: antidepressants have seven distinct mechanisms of action. *J Clin Psychiatry* 1998;59(suppl 4):5-14
4. Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. *Clin Pharmacol Ther* 1997;61:476-487
5. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. *J Clin Psychiatry* 1993;54:459-465
6. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. *Ann Pharmacother* 1998;32:1209-1215
7. Hirschfeld RMA. Sexual dysfunction in depression: disease- or drug-related? *Depression Anxiety* 1998;7:21-23
8. Patterson WM. Fluoxetine-induced sexual dysfunction [letter]. *J Clin Psychiatry* 1993;54:71
9. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. *Am J Psychiatry* 1995;152:1514-1516
10. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia. *Br J Psychiatry* 1986;148:217-218
11. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. *J Clin Psychiatry* 1992;53:207-209
12. Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine [letter]. *J Clin Psychiatry* 1992;53:212-213
13. Gelenberg AJ, Laukes C, McGahey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Waikoloa, Hawaii; Abstract PO#144, 253
14. Farah A. Lack of sexual adverse effects with mirtazapine. *Am J Health Syst Pharm* 1998;55:2195-2196
15. Koutouvides N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to SSRI treatment due to sexual dysfunction. *Eur Neuropsychopharmacol* 1997;7(suppl 2):S156
16. Montgomery S. Safety of mirtazapine: a review. *Int Clin Psychopharmacol* 1995;10(suppl):37-45
17. Baldwin DS, Thomas SC, Birtwistle J. Effects of antidepressant drugs on sexual function. *Int J Psychiatry Clin Pract* 1997;1:47-58

Andy Farah, M.D.

Greensboro, North Carolina

Obsessive-Compulsive Symptoms With Risperidone

Sir: The recent letters from Dr. Andrade¹ and Drs. Saxena and Bystritsky² regarding the worsening of antidepressant-treated obsessive-compulsive symptoms upon addition of risperidone did not address an additional issue—that there have been reports of risperidone-induced obsessive-compulsive symptoms.^{3,4} In addition, I recently had a patient who developed an obsessional image of a person's face that repeatedly appeared in his mind as he went about his activities. He did not know the person whose image he saw, and he became acutely

distressed by the recurring appearance of this image. This patient had a diagnosis of schizophrenia with no past history of obsessive-compulsive symptoms and had been on treatment with risperidone, 4 mg/day, for 18 months. He was also receiving sodium valproate, 1000 mg/day; benzhexol, 4 mg/day; and a depot injection of zuclopenthixol, 400 mg every 2 weeks. The recurrent images disappeared after the dosage of risperidone was decreased to 3 mg/day.

It is likely that risperidone's potent serotonin (5-HT₂) antagonism has a role in the occurrence of obsessive-compulsive symptoms. Combinations of a serotonin reuptake inhibitor (SRI) and risperidone therefore would require close monitoring for a possible exacerbation of obsessive-compulsive symptoms.

REFERENCES

1. Andrade C. Risperidone may worsen fluoxetine-treated OCD [letter with reply]. *J Clin Psychiatry* 1998;59:255-256
2. Saxena S, Bystritsky A. Reply to Andrade C: Risperidone may worsen fluoxetine-treated OCD [letter]. *J Clin Psychiatry* 1998;59:256
3. Alzaid K, Jones BD. Case report of risperidone-induced obsessive-compulsive symptoms [letter]. *J Clin Psychopharmacol* 1997;17:58-59
4. Mahendran R. Obsessional symptoms associated with risperidone treatment. *Aust N Z J Psychiatry* 1998;32:299-301

Rathi Mahendran, M.Med.(Psych)
Singapore

Dr. Andrade Replies

Sir: Dr. Mahendran presents a case of obsessive imagery in a schizophrenic patient. She suggests that risperidone was responsible for the phenomena. Militating against her argument is the long duration (18 months) of uneventful use of risperidone. Favoring her argument is the disappearance of symptoms when the dose of risperidone was lowered. In the absence of mention of potentially dysequilibrating and re-equilibrating psychopharmacologic or psychosocial events, it is assumed that none existed. Rechallenge with risperidone was not attempted. Essentially, the etiologic role of risperidone in this case, while possible, remains unconfirmed.

Dr. Mahendran observes that I did not address risperidone-induced obsessive-compulsive symptoms in my report; since the issue was peripheral to my subject, I had mentioned risperidone-induced *worsening* of such symptoms, but merely in passing. My report addressed a hazard of the risperidone-fluoxetine combination; Dr. Mahendran describes a hazard of risperidone monotherapy.

Dr. Mahendran suggests that 5-HT₂ receptor antagonism with risperidone may underlie its propensity to induce or worsen obsessive-compulsive symptoms. Although most authors would agree, I believe that the mechanisms are far more complex. Consider the following: serotonin reuptake inhibitors (SRIs), in the long term, induce compensatory down-regulation of several presynaptic and postsynaptic serotonergic receptors,¹ whereas risperidone produces a direct, functional blockade of these receptors.² In addition, SRI drugs produce downstream dopaminergic inhibition,³ whereas risperidone directly blocks dopamine receptors.² Such serotonergic and dopaminergic mechanisms may be therapeutically relevant in obsessive-compulsive disorder (OCD).^{4,5}

These similarities of action suggest that risperidone may potentiate the action of SRI drugs in OCD. So, why would risperidone monotherapy or rapid dose escalation with risperidone

precipitate or exacerbate obsessive-compulsive symptoms? The answer may lie in time-dependent changes: the described receptor actions of SRI drugs are delayed, whereas those of risperidone are immediate. Consequently, it is likely that SRI therapy primes the biological system in some hitherto unknown way, making later serotonergic and dopaminergic receptor changes therapeutic. Gradual dose escalation with risperidone, hypothetically, similarly allows the system to adapt. In contrast, risperidone monotherapy, rapid dose escalation, or high-dose treatment with risperidone overwhelms the receptors and does not allow the development of the putative compensatory therapeutic mechanisms.

This hypothesis explaining SRI-risperidone synergism has a homeopathic flavor. There is little better to offer, however, to explain the otherwise paradoxical observations that risperidone can both benefit as well as precipitate and/or worsen obsessive-compulsive symptoms, depending on the circumstances. In any case, Dr. Mahendran's concluding note is valid: that the SRI-risperidone combination requires close monitoring for possible exacerbation of obsessive-compulsive symptoms, a point which I, too, made in my report.

As a tailpiece: the patient described in my original letter⁶ remained moderately to severely impaired 6 months after his initial exacerbation of obsessive-compulsive symptoms associated with risperidone use. After obtaining informed consent, he was rechallenged with risperidone (1 mg/day); his existing dosage of fluoxetine (60 mg/day) was continued unchanged. Amelioration of obsessive-compulsive symptomatology was observed. After 1 month, the dosage of risperidone was raised to 2 mg/day. There was rapid loss of the accrued gains. The dosage of risperidone was therefore lowered and maintained at 1 mg/day; this dosage was associated with acceptable response. These observations fit the argument that has been offered for the mechanism of risperidone-fluoxetine synergism. Further research with *in vivo* chemical challenges may, however, provide more information about the mechanisms involved.

REFERENCES

1. Goodwin GM. How do antidepressants affect serotonin receptors? the role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. *J Clin Psychiatry* 1996;57(suppl 4):9-13
2. Leysen JE, Janssen PMF, Megens AAHP, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. *J Clin Psychiatry* 1994;55(5, suppl):5-12
3. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. *Am J Psychiatry* 1996;153:466-476
4. Austin LS, Lydiard B, Ballenger JC, et al. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. *Biol Psychiatry* 1991;30:225-232
5. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. *Arch Gen Psychiatry* 1994;51:302-308
6. Andrade C. Risperidone may worsen fluoxetine-treated OCD [letter with reply]. *J Clin Psychiatry* 1998;59:255-256

Chittaranjan Andrade, M.D.
Bangalore, India

Dr. Saxena Replies

Sir: In his letter, Dr. Mahendran correctly observes that the recent letters from Andrade¹ and from Saxena and Bystritsky² did not discuss the issue of risperidone-

induced obsessive-compulsive symptoms. However, both *de novo* obsessive-compulsive symptoms and exacerbations of obsessive-compulsive symptoms associated with risperidone and clozapine were reviewed in a previous report by our group³ on risperidone augmentation of SRI treatment for refractory OCD. In recent years, several more cases have added to our understanding of this phenomenon.

A review of the existing literature on obsessive-compulsive symptoms associated with atypical antipsychotics leads us to several general conclusions. First, obsessive-compulsive symptoms induced by atypical antipsychotics occur much more frequently in patients with schizophrenia and other primary psychotic illnesses than in patients with primary OCD or Tourette's disorder. Of the total of 17 patients with atypical antipsychotic-induced obsessive-compulsive symptoms (10 with clozapine,⁴⁻⁷ 6 with risperidone,⁸⁻¹² and 1 with olanzapine¹³) described in the literature, only 1 patient¹² had primary OCD without a comorbid primary schizophrenia spectrum illness. Patients with schizophrenia may have central serotonergic system abnormalities¹⁴ that predispose them to the development or worsening of obsessive-compulsive symptoms during treatment with atypical antipsychotics, which are all strong antagonists at a variety of 5-HT receptors.¹⁵ There have been reports of obsessive-compulsive symptoms improving or remaining unchanged in patients with Tourette's disorder^{16,17} and other OCD spectrum disorders¹⁸ treated with risperidone, but no reports of obsessive-compulsive symptoms worsening in those patients. A second conclusion is that obsessive-compulsive symptoms most often occur with atypical antipsychotic monotherapy and improve with the addition of an SRI.^{4,7,9,10,12} Third, obsessive-compulsive symptoms are seen much more commonly during treatment with higher doses of atypical antipsychotics (e.g., above 3 mg/day of risperidone or 10 mg/day of olanzapine) than with lower doses. Hence, starting at low doses and increasing slowly appear to be prudent recommendations for atypical antipsychotic augmentation of SRIs.

The mechanisms and risk factors for atypical antipsychotic-induced obsessive-compulsive symptoms remain unclear. Clearly, more research is needed to help practitioners avoid this troubling, if relatively uncommon, adverse effect. Such research will also improve our basic understanding of the neurobiological mediation of obsessive-compulsive symptoms.

REFERENCES

1. Andrade C. Risperidone may worsen fluoxetine-treated OCD [letter]. *J Clin Psychiatry* 1998;59:255-256
2. Saxena S, Bystritsky A. Reply to Andrade C: Risperidone may worsen fluoxetine-treated OCD [letter]. *J Clin Psychiatry* 1998;59:256
3. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. *J Clin Psychiatry* 1996;57:303-306
4. Cassidy SL, Thaker GK. Addition of fluoxetine to clozapine [letter]. *Am J Psychiatry* 1992;149:1274
5. Patil VJ. Development of transient obsessive-compulsive symptoms during treatment with clozapine [letter]. *Am J Psychiatry* 1992;149:272
6. Baker RW, Chengappa KNR, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. *J Clin Psychiatry* 1992;53:439-442
7. Patel B, Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment [letter]. *Am J Psychiatry* 1993;150:836
8. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [letter]. *J Clin Psychopharmacol* 1994;14:358-359
9. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia [letter]. *Am J Psychiatry* 1994;151:1714-1715

10. Dodt JE, Byerly MJ, Cuadros C, et al. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline [letter]. *Am J Psychiatry* 1997;154:582
11. Alzaid K, Jones BD. A case report of risperidone-induced obsessive-compulsive symptoms [letter]. *J Clin Psychopharmacol* 1997;17:58–59
12. Mahendran R. Obsessional symptoms associated with risperidone treatment. *Aust N Z J Psychiatry* 1998;32:299–301
13. Morrison D, Clark D, Goldfarb E, et al. Worsening of obsessive-compulsive symptoms following treatment with olanzapine [letter]. *Am J Psychiatry* 1998;155:855
14. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: post-mortem study. *Biol Psychiatry* 1997;42:529–545
15. Leysen JE, Gommeren W, Eens A. The biochemical profile of risperidone, a new antipsychotic. *J Pharmacol Exp Ther* 1988;247:661–670
16. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. *J Clin Psychiatry* 1996;57:29–31
17. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. *J Am Acad Child Adolesc Psychiatry* 1995;34:1147–1152
18. Stein DJ, Bouwer C, Hawkrigde S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. *J Clin Psychiatry* 1997;58:119–122
- mania and cycle acceleration: a controversy revisited. *Am J Psychiatry* 1995;152:1130–1138
4. El-Mallakh RS. New insights into the course and prognosis of bipolar illness. *Psychiatr Ann* 1997;27:478–481
5. Elliot KJ, Lewis S, El-Mallakh RS, et al. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia. *Ann Clin Psychiatry* 1994;6:197–203
6. Meshul CK, Casey DE. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. *Brain Res* 1989;489:338–346
7. Meshul CK, Janowsky A, Casey DE, et al. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. *Psychopharmacology (Berl)* 1992;106:45–52
8. Diefenbach TJ, Sloley BD, Goldberg JI. Neurite branch development of an identified serotonergic neuron from embryonic *Helisoma*: evidence for autoregulation by serotonin. *Dev Biol* 1995;167:282–293
9. Baker MW, Croll RP. Modulation of in vivo neuronal sprouting by serotonin in the adult CNS of the snail. *Cell Mol Neurobiol* 1996;16:561–576

Rif S. El-Mallakh, M.D.
Courtney Waltrip, M.D.
Christopher Peters, M.D.
Louisville, Kentucky

Sanjaya Saxena, M.D.
Los Angeles, California

Drs. Rothschild and Byrne Reply

Can Long-Term Antidepressant Use Be Depressogenic?

Sir: We appreciated the thoughtful review on the loss of antidepressant efficacy by Byrne and Rothschild.¹ We would like to put forward another possible explanation for the observation: long-term antidepressant use may be depressogenic. While this idea seems counterintuitive, there are reasons to seriously consider it. It has become clear that long-term use of antidepressants may destabilize patients with bipolar illness and give rise to dysphoric mixed states or rapid cycling,^{2–4} despite the fact that the initial effect of antidepressants in these subjects is therapeutically antidepressant.⁴

It is not uncommon for the chronic effect of a drug to be different from the initial effect. The best psychiatric example is that of the classic antipsychotics. The acute motoric effect of these drugs is bradykinetic (parkinsonism), but the chronic effect is hyperkinetic (tardive dyskinesic choreoathetoid movements).⁵ It has been postulated that a neuroleptic-induced increase in the number of synapses or perforated synapses^{6,7} may underlie this change. Similarly, neuronal sprouting of serotonergic neurons in the simple nervous system of snails can be modified with long-term alteration of serotonin concentrations,^{8,9} raising the possibility that antidepressant agents may cause neuroplastic changes. In other words, it is possible that antidepressant agents modify the hardwiring of neuronal synapses not only to render antidepressants ineffective but also to induce a resident, refractory depressive state. Although this proposal is purely speculative, the possibility needs to be considered.

REFERENCES

1. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. *J Clin Psychiatry* 1998;59:279–288
2. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. *Arch Gen Psychiatry* 1979;36:555–559
3. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced

Sir: We appreciate the comments of Dr. El-Mallakh and colleagues regarding our article¹ on the loss of antidepressant efficacy during maintenance therapy and their interesting suggestion that long-term antidepressant treatment may itself be depressogenic. In our article, we did offer this as one of several possible explanations for the phenomenon of loss of antidepressant efficacy. A change in the depressive disease due to medication therapy may be secondary to decreased dopaminergic tone owing to direct or indirect antidopaminergic effects of the antidepressant² or long-term changes in neurotransmitter systems, analogous to the changes by which antidepressants may destabilize patients with bipolar disorder. In addition, as was discussed in our article, tricyclic antidepressants may shorten the time between recurrences in unipolar depressive illness as well as in bipolar disorder.³ We also speculated that the long-term use of antidepressants could cause the depletion of one or more effector or precursor substances. For example, serotonin reuptake inhibition, by increasing extrasynaptic serotonin levels, could in theory cause a depletion of tryptophan in the brain by down-regulating the mechanism by which tryptophan is transported across the blood-brain barrier. Another example, as pointed out by Dr. El-Mallakh and colleagues, is that the neuronal sprouting of serotonergic neurons in the central nervous system of snails can be modified with long-term alteration of serotonin concentrations.^{4,5}

We agree with Dr. El-Mallakh and colleagues that the hypothesis that antidepressants may be depressogenic is speculative. We have not observed the phenomenon of antidepressant tachyphylaxis ("poop-out") to be a permanent or refractory state. In fact, there are many strategies discussed in our article¹ that are effective for treating a loss of antidepressant efficacy. One of these strategies, raising the dose of the antidepressant, is by far the most popular strategy⁶ and has been reported to produce full remission in 67% of patients who experience loss of antidepressant efficacy during fluoxetine treatment.⁷ If long-term treatment with antidepressants were depressogenic, one would expect that raising the dose of the antidepressant would make the patient worse, not better. Finally, as we discussed in our article, the clinical presentation of loss of antide-

pressant efficacy often differs from the initial presentation of the depressive syndrome, with depressed mood, apathy, and fatigue returning, but not the vegetative symptoms of depression. Clearly, further studies are needed to ascertain the rate of loss of antidepressant efficacy during maintenance treatment, whether it occurs more often with a particular type of antidepressant, and whether there are particular patients who are more at risk for the occurrence of loss of efficacy.

REFERENCES

1. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. *J Clin Psychiatry* 1998;59:279–288
2. McGrath P, Quitkin F, Klein D. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. *J Clin Psychopharmacol* 1995;15:289–291
3. Goodwin FK. The biology of recurrence: new directions for the pharmacologic bridge. *J Clin Psychiatry* 1989;50(12, suppl):40–44
4. Meshul CK, Janowsky A, Casey DE, et al. Effect of haloperidol and clozapine on the density of “perforated” synapses in caudate, nucleus accumbens, and medial prefrontal cortex. *Psychopharmacology (Berl)* 1992;106:45–52
5. Diefenbach TJ, Sloley BD, Goldberg JI. Neurite branch development of an identified serotonergic neuron from embryonic *Helisoma*: evidence for autoregulation by serotonin. *Dev Biol* 1995;167:282–293
6. Byrne S, Rothschild AJ. Psychiatrists’ responses to failure of maintenance therapy with antidepressants. *Psychiatr Serv* 1997;48:835–837
7. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. *J Clin Psychiatry* 1995;56:52–55

Anthony J. Rothschild, M.D.

Worcester, Massachusetts

Sarah E. Byrne, M.D.

Boston, Massachusetts

**Environmental Factors
in Panic Disorder**

Sir: Recently, mental health professionals in the Anxiety and Depression Clinic at Montefiore Medical Center, New York, noticed that a substantial subgroup of patients with panic disorder described hot weather and humidity as potential triggers of panic attacks. Since these findings raised important questions concerning the role of environmental factors in panic disorder, Montefiore clinicians developed a questionnaire to systematically evaluate the prevalence of hot weather, humidity, and various other conditions as catalysts for panic attacks. The questionnaire asked patients to rate on a scale from 0 to 3 whether panic was triggered or worsened by such conditions (0 = never, 1 = sometimes, 2 = most of the time, and 3 = always). Patients (N = 154) participated by completing the questionnaire and undergoing a semistructured interview to establish a DSM-IV diagnosis of panic disorder.

After review of the data, some patterns became quite evident. Over 53% of patients endorsed that humidity either caused or worsened panic attacks at least some of the time. Moreover, 65% responded that hot weather also had such an effect. While these findings are only preliminary, they clearly reinforce the notion that humidity and hot weather are important environmental factors in panic disorder. Two recent articles^{1,2} support such a conclusion, yet no study has ever systematically assessed the prevalence of hot weather and humidity as environmental factors in panic attacks. Furthermore, it is unclear whether such conditions are specific or nonspecific anxiogenic stressors. Regarding the latter, heat stress can induce autonomic arousal, resulting in symptoms such as increased heart rate and sweating,³ which may precipitate a panic attack in panic disorder patients who tend to be overly sensitive to visceral cues.

In addition to hot weather and humidity, other environmental factors such as organic solvents and gases have been reported to induce panic attacks in patients with multiple chemical sensitivity syndrome, which is a controversial syndrome and may represent a subgroup of panic disorder.⁴

Certainly, our findings may have a number of important clinical implications. First, mental health professionals should be advised as to the potential association that apparently exists between environmental factors and panic attacks. Such an awareness serves to lend credence to patient accounts that incorporate environmental conditions. Second, and more importantly, the findings present a potentially viable treatment strategy in managing panic attacks in environmentally dependent patient subgroups. In many patients who are adversely affected by hot weather and humidity, a cool, climate-controlled area is frequently able to subdue or alleviate attacks. To this end, clinicians could advise patients to properly moderate temperature in their home environment. In extreme cases, relocation to a suitable environment may be advisable. However, regardless of application, the findings suggest a new, optimistic avenue in the continuing fight against panic disorder.

REFERENCES

1. Cassano GB, Michelini S, Shear KM, et al. Panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. *Am J Psychiatry* 1997;154:27–38
2. Scupi BS, Maser JD, Uhde TW. The National Institute of Mental Health Panic Questionnaire: an instrument for assessing clinical characteristics of panic disorder. *J Nerv Ment Dis* 1992;180:566–577
3. Folinsbee LJ. Heat and air pollution. In: Pollock ML, Schmidt DH, eds. *Heart Disease and Rehabilitation*. 3rd ed. Champaign, Ill: Human Kinetics; 1995:327–335
4. Leznoff A. Provocative challenges in patients with multiple chemical sensitivity. *J Allergy Clin Immunol* 1997;99:438–442

Jeremy Asnis

Abdul Faisal, M.D.

William Sanderson, Ph.D.

Bronx, New York